HBPCF (Helix BioPharma) Total Equity : $-0.01 Mil (As of Jan. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Helix BioPharma Total Equity?

Helix BioPharma's total equity for the quarter that ended in Jan. 2025 was $-0.01 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Helix BioPharma Total Equity Historical Data

The historical data trend for Helix BioPharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Total Equity Chart

Helix BioPharma Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Total Equity

Get a 7-Day Free Trial

2.21

-1.11

0.25

-0.64

-0.07

Helix BioPharma Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Total Equity	Get a 7-Day Free Trial															-0.19	-0.26	-0.07	-0.99	-0.01

Helix BioPharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Helix BioPharma's Total Equity for the fiscal year that ended in Jul. 2024 is calculated as

Total Equity	=	Total Assets(Q: Jul. 2024 )	-	Total Liabilities(Q: Jul. 2024 )
	=	1.086	-	1.151
	=	-0.07

Helix BioPharma's Total Equity for the quarter that ended in Jan. 2025 is calculated as

Total Equity	=	Total Assets(Q: Jan. 2025 )	-	Total Liabilities(Q: Jan. 2025 )
	=	1.558	-	1.571
	=	-0.01

Helix BioPharma Total Equity Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

HBP0:Germany HBP:Canada

Address

40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4

Website

https://www.helixbiopharma.com

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.